Annual CFO
-$32.97 M
-$1.91 M-6.15%
31 December 2023
Summary:
Galectin Therapeutics annual cash flow from operations is currently -$32.97 million, with the most recent change of -$1.91 million (-6.15%) on 31 December 2023. During the last 3 years, it has fallen by -$12.36 million (-60.02%). GALT annual CFO is now -1732.10% below its all-time high of -$1.80 million, reached on 31 December 2001.GALT Cash From Operations Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly CFO
-$8.54 M
-$205.00 K-2.46%
30 September 2024
Summary:
Galectin Therapeutics quarterly cash flow from operations is currently -$8.54 million, with the most recent change of -$205.00 thousand (-2.46%) on 30 September 2024. Over the past year, it has dropped by -$901.00 thousand (-11.80%). GALT quarterly CFO is now -1600.80% below its all-time high of -$502.00 thousand, reached on 31 December 2008.GALT Quarterly CFO Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
TTM CFO
-$33.68 M
-$901.00 K-2.75%
30 September 2024
Summary:
Galectin Therapeutics TTM cash flow from operations is currently -$33.68 million, with the most recent change of -$901.00 thousand (-2.75%) on 30 September 2024. Over the past year, it has increased by +$1.82 million (+5.14%). GALT TTM CFO is now -5229.64% below its all-time high of -$631.90 thousand, reached on 31 March 2002.GALT TTM CFO Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
GALT Cash From Operations Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | -6.2% | -11.8% | +5.1% |
| 3 y3 years | -60.0% | -70.8% | -47.9% |
| 5 y5 years | -223.8% | -478.9% | -270.3% |
GALT Cash From Operations High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3 years | -60.0% | at low | -81.6% | +29.5% | -47.9% | +7.0% |
| 5 y | 5 years | -223.8% | at low | -478.9% | +29.5% | -270.3% | +7.0% |
| alltime | all time | -1732.1% | at low | -1600.8% | +29.5% | -5229.6% | +7.0% |
Galectin Therapeutics Cash From Operations History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2024 | - | -$8.54 M(+2.5%) | -$33.68 M(+2.7%) |
| June 2024 | - | -$8.33 M(-31.2%) | -$32.78 M(-4.4%) |
| Mar 2024 | - | -$12.11 M(+157.4%) | -$34.28 M(+4.0%) |
| Dec 2023 | -$32.97 M(+6.1%) | -$4.70 M(-38.4%) | -$32.97 M(-7.1%) |
| Sept 2023 | - | -$7.64 M(-22.3%) | -$35.50 M(-2.0%) |
| June 2023 | - | -$9.83 M(-8.9%) | -$36.21 M(+7.1%) |
| Mar 2023 | - | -$10.79 M(+49.1%) | -$33.81 M(+8.9%) |
| Dec 2022 | -$31.06 M(+27.8%) | -$7.24 M(-13.3%) | -$31.06 M(+0.9%) |
| Sept 2022 | - | -$8.35 M(+12.4%) | -$30.77 M(+12.2%) |
| June 2022 | - | -$7.43 M(-7.6%) | -$27.42 M(+5.6%) |
| Mar 2022 | - | -$8.04 M(+15.7%) | -$25.97 M(+6.8%) |
| Dec 2021 | -$24.31 M(+18.0%) | -$6.95 M(+39.1%) | -$24.31 M(+6.7%) |
| Sept 2021 | - | -$5.00 M(-16.4%) | -$22.77 M(-12.4%) |
| June 2021 | - | -$5.98 M(-6.3%) | -$25.98 M(+14.9%) |
| Mar 2021 | - | -$6.38 M(+17.9%) | -$22.61 M(+9.8%) |
| Dec 2020 | -$20.60 M(+89.9%) | -$5.41 M(-34.1%) | -$20.60 M(+8.7%) |
| Sept 2020 | - | -$8.21 M(+215.4%) | -$18.95 M(+55.2%) |
| June 2020 | - | -$2.60 M(-40.4%) | -$12.21 M(+2.3%) |
| Mar 2020 | - | -$4.37 M(+16.3%) | -$11.94 M(+10.0%) |
| Dec 2019 | -$10.85 M(+6.6%) | -$3.76 M(+154.8%) | -$10.85 M(+19.3%) |
| Sept 2019 | - | -$1.48 M(-36.7%) | -$9.10 M(-1.1%) |
| June 2019 | - | -$2.33 M(-29.0%) | -$9.20 M(-7.5%) |
| Mar 2019 | - | -$3.28 M(+63.6%) | -$9.95 M(-2.3%) |
| Dec 2018 | -$10.18 M(-35.9%) | -$2.01 M(+27.3%) | -$10.18 M(-15.7%) |
| Sept 2018 | - | -$1.58 M(-48.8%) | -$12.08 M(-11.3%) |
| June 2018 | - | -$3.08 M(-12.4%) | -$13.62 M(-12.4%) |
| Mar 2018 | - | -$3.52 M(-9.9%) | -$15.54 M(-2.2%) |
| Dec 2017 | -$15.89 M(-3.2%) | -$3.90 M(+25.0%) | -$15.89 M(-5.7%) |
| Sept 2017 | - | -$3.12 M(-37.6%) | -$16.85 M(-1.9%) |
| June 2017 | - | -$5.00 M(+29.5%) | -$17.17 M(+2.3%) |
| Mar 2017 | - | -$3.86 M(-20.6%) | -$16.78 M(+2.3%) |
| Dec 2016 | -$16.41 M(-3.4%) | -$4.87 M(+41.3%) | -$16.41 M(+1.6%) |
| Sept 2016 | - | -$3.44 M(-25.3%) | -$16.14 M(-9.2%) |
| June 2016 | - | -$4.61 M(+32.1%) | -$17.79 M(+10.0%) |
| Mar 2016 | - | -$3.49 M(-24.1%) | -$16.16 M(-4.8%) |
| Dec 2015 | -$16.98 M(+36.7%) | -$4.60 M(-9.5%) | -$16.98 M(+9.6%) |
| Sept 2015 | - | -$5.08 M(+70.2%) | -$15.49 M(+13.2%) |
| June 2015 | - | -$2.99 M(-30.7%) | -$13.69 M(+4.4%) |
| Mar 2015 | - | -$4.31 M(+38.5%) | -$13.12 M(+5.6%) |
| Dec 2014 | -$12.43 M(+66.0%) | -$3.11 M(-5.1%) | -$12.43 M(+13.4%) |
| Sept 2014 | - | -$3.28 M(+36.1%) | -$10.96 M(+19.6%) |
| June 2014 | - | -$2.41 M(-33.4%) | -$9.16 M(+5.5%) |
| Mar 2014 | - | -$3.62 M(+119.9%) | -$8.68 M(+16.0%) |
| Dec 2013 | -$7.48 M | -$1.65 M(+11.0%) | -$7.48 M(-1.4%) |
| Sept 2013 | - | -$1.48 M(-23.2%) | -$7.59 M(-7.3%) |
| June 2013 | - | -$1.93 M(-20.3%) | -$8.19 M(-3.0%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Mar 2013 | - | -$2.42 M(+38.4%) | -$8.44 M(+12.5%) |
| Dec 2012 | -$7.50 M(+32.1%) | -$1.75 M(-15.8%) | -$7.50 M(+2.9%) |
| Sept 2012 | - | -$2.08 M(-4.8%) | -$7.29 M(+12.8%) |
| June 2012 | - | -$2.18 M(+47.0%) | -$6.46 M(+11.5%) |
| Mar 2012 | - | -$1.49 M(-3.6%) | -$5.79 M(+2.1%) |
| Dec 2011 | -$5.68 M(+83.0%) | -$1.54 M(+23.3%) | -$5.68 M(+20.3%) |
| Sept 2011 | - | -$1.25 M(-17.5%) | -$4.72 M(+9.9%) |
| June 2011 | - | -$1.52 M(+10.9%) | -$4.29 M(+15.8%) |
| Mar 2011 | - | -$1.37 M(+134.5%) | -$3.71 M(+19.5%) |
| Dec 2010 | -$3.10 M(-20.2%) | -$583.00 K(-29.5%) | -$3.10 M(-7.2%) |
| Sept 2010 | - | -$827.00 K(-11.2%) | -$3.34 M(-7.7%) |
| June 2010 | - | -$931.00 K(+22.3%) | -$3.62 M(-5.8%) |
| Mar 2010 | - | -$761.00 K(-7.4%) | -$3.84 M(-1.1%) |
| Dec 2009 | -$3.89 M(-16.7%) | -$822.00 K(-25.7%) | -$3.89 M(+9.0%) |
| Sept 2009 | - | -$1.11 M(-4.0%) | -$3.57 M(+4.8%) |
| June 2009 | - | -$1.15 M(+43.2%) | -$3.40 M(-14.3%) |
| Mar 2009 | - | -$805.00 K(+60.4%) | -$3.97 M(-14.9%) |
| Dec 2008 | -$4.67 M(-14.9%) | -$502.00 K(-46.8%) | -$4.67 M(-14.1%) |
| Sept 2008 | - | -$943.00 K(-45.2%) | -$5.43 M(-2.4%) |
| June 2008 | - | -$1.72 M(+14.8%) | -$5.56 M(0.0%) |
| Mar 2008 | - | -$1.50 M(+18.1%) | -$5.56 M(+1.5%) |
| Dec 2007 | -$5.48 M(-18.9%) | -$1.27 M(+18.2%) | -$5.48 M(-0.2%) |
| Sept 2007 | - | -$1.07 M(-37.6%) | -$5.50 M(-7.4%) |
| June 2007 | - | -$1.72 M(+21.3%) | -$5.93 M(-6.1%) |
| Mar 2007 | - | -$1.42 M(+10.8%) | -$6.32 M(-6.5%) |
| Dec 2006 | -$6.76 M(+10.3%) | -$1.28 M(-15.3%) | -$6.76 M(-3.8%) |
| Sept 2006 | - | -$1.51 M(-28.2%) | -$7.02 M(+3.1%) |
| June 2006 | - | -$2.11 M(+13.5%) | -$6.81 M(+6.6%) |
| Mar 2006 | - | -$1.86 M(+20.1%) | -$6.39 M(+4.3%) |
| Dec 2005 | -$6.13 M(-3.3%) | -$1.55 M(+18.7%) | -$6.13 M(-3.2%) |
| Sept 2005 | - | -$1.30 M(-22.9%) | -$6.33 M(-7.3%) |
| June 2005 | - | -$1.69 M(+6.1%) | -$6.83 M(-0.8%) |
| Mar 2005 | - | -$1.59 M(-8.9%) | -$6.89 M(+8.7%) |
| Dec 2004 | -$6.33 M(+52.5%) | -$1.75 M(-3.2%) | -$6.33 M(+9.1%) |
| Sept 2004 | - | -$1.80 M(+3.4%) | -$5.80 M(+12.7%) |
| June 2004 | - | -$1.75 M(+68.3%) | -$5.15 M(+21.8%) |
| Mar 2004 | - | -$1.04 M(-14.9%) | -$4.23 M(+1.9%) |
| Dec 2003 | -$4.15 M(+39.2%) | -$1.22 M(+5.9%) | -$4.15 M(+7.6%) |
| Sept 2003 | - | -$1.15 M(+39.5%) | -$3.86 M(+9.9%) |
| June 2003 | - | -$824.80 K(-13.9%) | -$3.51 M(+6.2%) |
| Mar 2003 | - | -$958.40 K(+3.5%) | -$3.31 M(+10.9%) |
| Dec 2002 | -$2.98 M(+65.8%) | -$926.30 K(+15.3%) | -$2.98 M(+45.0%) |
| Sept 2002 | - | -$803.20 K(+29.3%) | -$2.06 M(+64.1%) |
| June 2002 | - | -$621.20 K(-1.7%) | -$1.25 M(+98.3%) |
| Mar 2002 | - | -$631.90 K | -$631.90 K |
| Dec 2001 | -$1.80 M | - | - |
FAQ
- What is Galectin Therapeutics annual cash flow from operations?
- What is the all time high annual CFO for Galectin Therapeutics?
- What is Galectin Therapeutics annual CFO year-on-year change?
- What is Galectin Therapeutics quarterly cash flow from operations?
- What is the all time high quarterly CFO for Galectin Therapeutics?
- What is Galectin Therapeutics quarterly CFO year-on-year change?
- What is Galectin Therapeutics TTM cash flow from operations?
- What is the all time high TTM CFO for Galectin Therapeutics?
- What is Galectin Therapeutics TTM CFO year-on-year change?
What is Galectin Therapeutics annual cash flow from operations?
The current annual CFO of GALT is -$32.97 M
What is the all time high annual CFO for Galectin Therapeutics?
Galectin Therapeutics all-time high annual cash flow from operations is -$1.80 M
What is Galectin Therapeutics annual CFO year-on-year change?
Over the past year, GALT annual cash flow from operations has changed by -$1.91 M (-6.15%)
What is Galectin Therapeutics quarterly cash flow from operations?
The current quarterly CFO of GALT is -$8.54 M
What is the all time high quarterly CFO for Galectin Therapeutics?
Galectin Therapeutics all-time high quarterly cash flow from operations is -$502.00 K
What is Galectin Therapeutics quarterly CFO year-on-year change?
Over the past year, GALT quarterly cash flow from operations has changed by -$901.00 K (-11.80%)
What is Galectin Therapeutics TTM cash flow from operations?
The current TTM CFO of GALT is -$33.68 M
What is the all time high TTM CFO for Galectin Therapeutics?
Galectin Therapeutics all-time high TTM cash flow from operations is -$631.90 K
What is Galectin Therapeutics TTM CFO year-on-year change?
Over the past year, GALT TTM cash flow from operations has changed by +$1.82 M (+5.14%)